I am Yang Gil-an and the Chief Executive Officer of CorestemChemon.

Corestem, specializing in stem cell therapies, and Chemon, leading the domestic non-clinical CRO market, have joined forces with the great ambition of global expansion in December 2022, becoming one family.

With the best technology and talent we possess, we aim to maximize synergy and transform into a customer-oriented company that prioritizes the needs of society, while maintaining a shareholder-friendly management approach and fulfilling our responsibilities and respect towards investors.

To achieve this, we will strengthen our management, engage in continuous research and development, and pursue value investments, with the goal of enhancing the well-being of all humanity and creating value appreciation in the lives of people worldwide.

We will make every effort to become a global pharmaceutical company that contributes to the welfare of mankind.

Once again, we express our gratitude to everyone and kindly ask for your continued support and encouragement for CorestemChemon.

Yours faithfully,
Gil-An Yang, CEO of CORESTEMCHEMON